Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 527

Sort by

Sort Order Select

Journal Articles

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Blood (2020) 136 (7): 823–830.

https://doi.org/10.1182/blood.2019004583

Published: 2020

Includes: Supplemental data

Journal Articles

Risk Factors for Increased Length of Stay (LOS) in Patients with Hematological Malignancies Electively Admitted for Chemotherapy

Christopher E. Wee, MD, Jilan Kubusek, PharmD, Irbaz Riaz, MDMMSc, Robert Wolf, PharmD, RPh, Julian R Molina, MD PhD, Naseema Gangat, MBBS

Blood (2019) 134 (Supplement_1): 2138.

https://doi.org/10.1182/blood-2019-127367

Published: 2019

Journal Articles

The Impact of Diagnosis to Treatment Interval on the Outcome of Patients with Acute Myeloid Leukemia

Samah Nassereddine, MD, Kimberley Doucette, MD MSc, Vanya Aggarwal, Richard Amdur, PhD, Imad A. Tabbara, MD, Catherine E. Lai, MD

Blood (2019) 134 (Supplement_1): 2212.

https://doi.org/10.1182/blood-2019-124150

Published: 2019

Journal Articles

Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1 st FLOR' Study

Allison Barraclough, Geoff Chong, Michael Gilbertson, Andrew Grigg, Leonid Churilov, Tineke Fancourt, David Ritchie, MD PhD, Rachel Koldej, Rishu Agarwal, Kate Manos, Charmaine Smith, Kristen Houdyk, Joanne Hawking, Eliza Hawkes

Blood (2019) 134 (Supplement_1): 1523.

https://doi.org/10.1182/blood-2019-123908

Published: 2019

Journal Articles

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Juan Carlos Ramos, MD BS, Joseph Sparano, MD, Page C. Moore, PhD, Eric Siegel, Jeannette Y Lee, PhD, Erin G. Reid, MD MS, Richard F. Ambinder, MD, Amy Chadburn, MD, Paul G. Rubinstein, MD, Christine Durand, Ethel Cesarman, MD PhD, Lee Ratner, MD PhD, Robert A Baiocchi, MD PhD, David M. Aboulafia, MD, Lawrence D Kaplan, MD, Adam Capoferri, Ronald T. Mitsuyasu, MD, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1588.

https://doi.org/10.1182/blood-2019-129687

Published: 2019

Journal Articles

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)

Madan Jagasia, MBBS, MS, MMHC, Amandeep Salhotra, MD, Carlos R. Bachier, MD, Behyar Zoghi, MD, PhD, FACP, Aleksandr Lazaryan, MDPhDMPH, Daniel J. Weisdorf, MD, James Essell, MD, Laurie S. Green, MD, Olivier Schueller, PhD, Lindy Huang, Zhongming Yang, PhD, David Eiznhamer, PhD, Sanjay K. Aggarwal, MD, Bruce R. Blazar, MD, Stephanie J. Lee, MD MPH

Blood (2019) 134 (Supplement_1): 872.

https://doi.org/10.1182/blood-2019-125986

Published: 2019

Journal Articles

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

Neha Mehta-Shah, MD, Peter A. Riedell, MD, Nancy L. Bartlett, MD, Amanda F Cashen, MD, Brad S. Kahl, MD, Todd A Fehniger, MD PhD, Chaz Moreno, Jingxia Liu, MS, PhD, Kenneth R. Carson, MD PhD

Blood (2019) 134 (Supplement_1): 1550.

https://doi.org/10.1182/blood-2019-124185

Published: 2019

Journal Articles

Major Deviations in the Delivery of Induction Chemotherapy Are Associated with an Increased Risk of Relapse in Acute Lymphoblastic Leukaemia: Results from UKALL2003

Rachael E Hough, MD, Amy A Kirkwood, Sujith Samarasinghe, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, Nicholas John Goulden, MD PhD MRCPath, Ajay Vora

Blood (2019) 134 (Supplement_1): 2579.

https://doi.org/10.1182/blood-2019-127223

Published: 2019

Journal Articles

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

Brian Giacopelli, BS, Kari G. Chaffee, MS, Yue-zhong Wu, MSc, John C. Byrd, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Christopher C. Oakes, PhD

Blood (2019) 134 (Supplement_1): 3022.

https://doi.org/10.1182/blood-2019-123564

Published: 2019

Journal Articles

Long-Time Follow-up of 888 Patients Diagnosed with CLL on a Single Center: Comorbidities, Time-to-Treatment and Comparison between Treated and Untreated Patients

Felix Keil, MD, Lisa Obenaus, BSc, Victor Rathkolb, MD, Michael Leiner, MD, Robert Spörk, MSc, Elisabeth Koller, MD, Ernst Forjan, MD, Ralph Simanek, MD, Michael Panny, MD, Daniel Lechner, MD, Alexandra Böhm, MD, Anabel Schönmetzler, MD, Theresia Kornberger, MD, Thomas Noesslinger, MD

Blood (2019) 134 (Supplement_1): 5458.

https://doi.org/10.1182/blood-2019-122024

Published: 2019

Journal Articles

Androgen Receptor Targeting with Enzalutamide for Mantle Cell Lymphoma: Safety and Efficacy

Victor A. Chow, MD, Paul S. Martin, MD, Stephen D. Smith, MD, Brian G. Till, MD, Solomon A. Graf, MD, Kerstin L. Edlefsen, MD, Lindsay M. Hannan, MD MSPH, Elahe A. Mostaghel, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5254.

https://doi.org/10.1182/blood-2019-125462

Published: 2019

Journal Articles

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Reem Karmali, MD, Hagop Youssoufian, MD, Kam Sprott, PhD, David T. Weaver, PhD, Narayana Narasimhan, Stephanie Lustgarten, PhD, Gloria Patrick, Alena Zalutskaya, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 5251.

https://doi.org/10.1182/blood-2019-124406

Published: 2019

Journal Articles

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

Pallavi Mehta, MD DM, Neha Yadav, BDS , MBA, Mohan Bhaarat, Sumeet Prakash Mirgh, MBBS, MDDM, Vishvdeep Khushoo, MBBS, MDDM, Shinto Francis Thekuddan, MBBS, MDDM, Narendra Agrawal, MD DM, Rayaz Ahmed, MDDM, Dinesh Bhurani, MD DM, FRCPA

Blood (2019) 134 (Supplement_1): 5572.

https://doi.org/10.1182/blood-2019-131674

Published: 2019

Journal Articles

Real World Treatment Patterns and Toxicity Among Elderly Patients with Multiple Myeloma

Jesus D Gonzalez-Lugo, MD, Ana Acuna-Villaorduna, MD, Joshua Heisler, MD, Niyati Goradia, MBBS, Daniel Cole, MD, Mateo Mejia Saldarriaga, MD, Aditi Shastri, MD, Gurbakhash Kaur, MD, Ira Braunschweig, MD, Noah Kornblum, MD, Amit Verma, MBBS, Murali Janakiram, MD MS, Ioannis Mantzaris, MD MS

Blood (2019) 134 (Supplement_1): 5571.

https://doi.org/10.1182/blood-2019-131114

Published: 2019

Journal Articles

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

Blood (2019) 134 (Supplement_1): 4235.

https://doi.org/10.1182/blood-2019-129614

Published: 2019

Journal Articles

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

Paolo Milani, MD PhD, Francesca Fazio, MD, Marco Basset, MD, Tamara Berno, MD, Alessandra Larocca, Andrea Foli, MD, Marcello Riva, MD, Stefania Oliva, Jessica Ripepi, Mario Nuvolone, MD PhD, Maria Teresa Petrucci, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1860.

https://doi.org/10.1182/blood-2019-130675

Published: 2019

Journal Articles

Lenalidomide Maintenance Prolongs Progression-Free Survival and Does Not Impact the Aggressiveness of Clinical Relapse: Data from Long-Term Follow up of the Myeloma XI Trial

Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, Kara-Louise Royle, MSc, David Cairns, MSc, PhD, Gordon Cook, Mark T Drayson, MB ChB, PhD FRCPath, Walter M Gregory, PhD, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Roger G. Owen, MD, Nigel H. Russell, MD, Gareth Morgan, MDPhDFRCP, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD

Blood (2019) 134 (Supplement_1): 1889.

https://doi.org/10.1182/blood-2019-126103

Published: 2019

Journal Articles

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Christoph Röllig, MD MSC, Michael Kramer, M.Sc., Christoph Schliemann, Jan-Henrik Mikesch, MD, Björn Steffen, MD, Alwin Krämer, MD, Tim Sauer, MD, Mathias Hänel, MD, Regina Herbst, MD, Kerstin Schäfer-Eckart, MD, Richard Noppeney, MD, Edgar Jost, MD, Tim H Brümmendorf, MD, Stefan W Krause, MD, Volker Kunzmann, MD PhD, Hermann Einsele, MD, Sebastian Scholl, Andreas Hochhaus, MD, Lars R. Fransecky, MD, Martin Kaufmann, MD, Andreas Neubauer, MD, Dirk Niemann, MD, Markus Schaich, MD, Norbert Frickhofen, MD, Alexander Kiani, Frank Heits, MD, Ulrich Krümpelmann, Ulrich Kaiser, MD, Johannes Kullmer, Maxi Wass, MD, Stefan Klein, MD, Malte Von Bonin, Jan Moritz Middeke, MD, Christian Thiede, MD, Friedrich Stoelzel, MD, Johannes Schetelig, MDMSc, Gerhard Ehninger, MD, Claudia D Baldus, Carsten Müller-Tidow, MD, Uwe Platzbecker, Hubert Serve, MD, Martin Bornhäuser, MD

Blood (2019) 134 (Supplement_1): 13.

https://doi.org/10.1182/blood-2019-123717

Published: 2019

Journal Articles

40% of Females with Mantle Cell Lymphoma Are Managed with Initial Observation: Results from the MCL Biobank Observational Study

Rory McCulloch, FRCPath, MRCP, MBBS, Alexandra Smith, PhD, Brian Wainman, Wendy Ingram, Amelia Lewis, Matthew Hawkins, Nicola Crosbie, Andrew Pettitt, FRCPath, PhD, Simon Rule

Blood (2019) 134 (Supplement_1): 2821.

https://doi.org/10.1182/blood-2019-128340

Published: 2019

Journal Articles

Real World Population-Based Exploration of the Pathology Subtyping and Treatment-Modalities of Diffuse Large B-Cell Lymphoma in Belgium in Relation to Survival

Willem Daneels, MD, Michael Rosskamp, PhD, Gilles Macq, PhD, Estabraq Ismael Saadoon, MD, Anke De Geyndt, PhD, Fritz Offner, MD, Helene A. Poirel, MD PhD

Blood (2019) 134 (Supplement_1): 2894.

https://doi.org/10.1182/blood-2019-122443

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Risk Factors for Increased Length of Stay (LOS) in Patients with Hematological Malignancies Electively Admitted for Chemotherapy

The Impact of Diagnosis to Treatment Interval on the Outcome of Patients with Acute Myeloid Leukemia

Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1 st FLOR' Study

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

Major Deviations in the Delivery of Induction Chemotherapy Are Associated with an Increased Risk of Relapse in Acute Lymphoblastic Leukaemia: Results from UKALL2003

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

Long-Time Follow-up of 888 Patients Diagnosed with CLL on a Single Center: Comorbidities, Time-to-Treatment and Comparison between Treated and Untreated Patients

Androgen Receptor Targeting with Enzalutamide for Mantle Cell Lymphoma: Safety and Efficacy

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

Real World Treatment Patterns and Toxicity Among Elderly Patients with Multiple Myeloma

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

Lenalidomide Maintenance Prolongs Progression-Free Survival and Does Not Impact the Aggressiveness of Clinical Relapse: Data from Long-Term Follow up of the Myeloma XI Trial

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

40% of Females with Mantle Cell Lymphoma Are Managed with Initial Observation: Results from the MCL Biobank Observational Study

Real World Population-Based Exploration of the Pathology Subtyping and Treatment-Modalities of Diffuse Large B-Cell Lymphoma in Belgium in Relation to Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only